Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.

Humphrey JM, Movsesian M, Am Ende CW, Becker SL, Chappie TA, Jenkinson S, Liras JL, Liras S, Orozco C, Pandit J, Vajdos FF, Vandeput F, Yang E, Menniti FS.

J Med Chem. 2018 May 24;61(10):4635-4640. doi: 10.1021/acs.jmedchem.8b00374. Epub 2018 May 10.

PMID:
29718668
2.

Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.

Patel NS, Klett J, Pilarzyk K, Lee DI, Kass D, Menniti FS, Kelly MP.

Neurobiol Aging. 2018 May;65:217-234. doi: 10.1016/j.neurobiolaging.2018.01.019. Epub 2018 Feb 5.

3.

NMDA Receptors in the Central Nervous System.

Hansen KB, Yi F, Perszyk RE, Menniti FS, Traynelis SF.

Methods Mol Biol. 2017;1677:1-80. doi: 10.1007/978-1-4939-7321-7_1.

PMID:
28986865
4.

Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors.

Yi F, Mou TC, Dorsett KN, Volkmann RA, Menniti FS, Sprang SR, Hansen KB.

Neuron. 2016 Sep 21;91(6):1316-1329. doi: 10.1016/j.neuron.2016.08.014. Epub 2016 Sep 8.

5.

N-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?

Katz DM, Menniti FS, Mather RJ.

Biol Psychiatry. 2016 May 1;79(9):710-2. doi: 10.1016/j.biopsych.2016.03.1045. No abstract available.

6.

MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.

Volkmann RA, Fanger CM, Anderson DR, Sirivolu VR, Paschetto K, Gordon E, Virginio C, Gleyzes M, Buisson B, Steidl E, Mierau SB, Fagiolini M, Menniti FS.

PLoS One. 2016 Feb 1;11(2):e0148129. doi: 10.1371/journal.pone.0148129. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151452.

7.

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy.

Nagy D, Stoiljkovic M, Menniti FS, Hajós M.

Neuropsychopharmacology. 2016 May;41(6):1486-94. doi: 10.1038/npp.2015.298. Epub 2015 Sep 25.

8.

Translational psychiatry--light at the end of the tunnel.

Jones KA, Menniti FS, Sivarao DV.

Ann N Y Acad Sci. 2015 May;1344:1-11. doi: 10.1111/nyas.12725. Epub 2015 Mar 9. Review.

PMID:
25752480
9.

Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.

Uthayathas S, Masilamoni GJ, Shaffer CL, Schmidt CJ, Menniti FS, Papa SM.

Neuropharmacology. 2014 Feb;77:257-67.

10.

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Shaffer CL, Hurst RS, Scialis RJ, Osgood SM, Bryce DK, Hoffmann WE, Lazzaro JT, Hanks AN, Lotarski S, Weber ML, Liu J, Menniti FS, Schmidt CJ, Hajós M.

J Pharmacol Exp Ther. 2013 Oct;347(1):212-24. doi: 10.1124/jpet.113.204735. Epub 2013 Jul 30.

PMID:
23899905
11.

PDE4 as a target for cognition enhancement.

Richter W, Menniti FS, Zhang HT, Conti M.

Expert Opin Ther Targets. 2013 Sep;17(9):1011-27. doi: 10.1517/14728222.2013.818656. Epub 2013 Jul 25. Review.

12.

Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.

Uthayathas S, Shaffer CL, Menniti FS, Schmidt CJ, Papa SM.

J Neurosci Methods. 2013 Apr 30;215(1):97-102. doi: 10.1016/j.jneumeth.2013.02.004. Epub 2013 Feb 16.

13.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

14.

The distribution of phosphodiesterase 2A in the rat brain.

Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O'Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS.

Neuroscience. 2012 Dec 13;226:145-55. doi: 10.1016/j.neuroscience.2012.09.011. Epub 2012 Sep 19.

15.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S.

J Med Chem. 2012 Nov 8;55(21):9045-54. doi: 10.1021/jm3007799. Epub 2012 Jul 25.

PMID:
22780914
16.

A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.

Menniti FS, Ren J, Sietsma DK, Som A, Nelson FR, Stephenson DT, Tate BA, Finklestein SP.

Restor Neurol Neurosci. 2012;30(4):283-9. doi: 10.3233/RNN-2012-110187.

PMID:
22596355
17.

PDE inhibition and cognition enhancement.

Blokland A, Menniti FS, Prickaerts J.

Expert Opin Ther Pat. 2012 Apr;22(4):349-54. doi: 10.1517/13543776.2012.674514. Review. No abstract available.

PMID:
22475506
18.

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.

Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti FS, Steinbusch HW, Prickaerts J.

Neurobiol Learn Mem. 2012 May;97(4):370-9. doi: 10.1016/j.nlm.2012.02.008. Epub 2012 Mar 8.

PMID:
22426465
19.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
20.

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR.

PLoS One. 2010 Oct 15;5(10):e13417. doi: 10.1371/journal.pone.0013417.

21.

Glutamate receptor ion channels: structure, regulation, and function.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.

Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. Review. Erratum in: Pharmacol Rev. 2014 Oct;66(4):1141.

22.

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA.

Behav Brain Res. 2010 Sep 1;212(1):41-8. doi: 10.1016/j.bbr.2010.03.039. Epub 2010 Mar 27.

PMID:
20347881
23.

Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S.

J Med Chem. 2009 Dec 24;52(24):7946-9. doi: 10.1021/jm9015334.

PMID:
19919087
24.

Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.

Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS.

Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18225-30. doi: 10.1073/pnas.0907635106. Epub 2009 Oct 14.

25.

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ.

Neuropharmacology. 2010 Feb;58(2):444-51. doi: 10.1016/j.neuropharm.2009.09.008. Epub 2009 Sep 16.

PMID:
19765598
26.

Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.

Menniti FS, Ren J, Coskran TM, Liu J, Morton D, Sietsma DK, Som A, Stephenson DT, Tate BA, Finklestein SP.

J Pharmacol Exp Ther. 2009 Dec;331(3):842-50. doi: 10.1124/jpet.109.156919. Epub 2009 Sep 3.

PMID:
19729580
27.

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.

Helal CJ, Kang Z, Lucas JC, Gant T, Ahlijanian MK, Schachter JB, Richter KE, Cook JM, Menniti FS, Kelly K, Mente S, Pandit J, Hosea N.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5703-7. doi: 10.1016/j.bmcl.2009.08.019. Epub 2009 Aug 8.

PMID:
19700321
28.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S.

J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k.

PMID:
19630403
29.

Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species.

Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O'Donnell MM, Muravnick KB, Menniti FS, Kleiman RJ, Morton D.

J Histochem Cytochem. 2009 Oct;57(10):933-49. doi: 10.1369/jhc.2009.953471. Epub 2009 Jun 8.

30.

Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes.

Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M.

Biol Reprod. 2009 Sep;81(3):595-604. doi: 10.1095/biolreprod.109.077768. Epub 2009 May 27.

31.

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.

Giampà C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, Fusco FR.

Neurobiol Dis. 2009 Jun;34(3):450-6. doi: 10.1016/j.nbd.2009.02.014. Epub 2009 Mar 9.

PMID:
19281846
32.

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.

Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR.

J Pharmacol Exp Ther. 2009 Mar;328(3):785-95. doi: 10.1124/jpet.108.146332. Epub 2008 Dec 4.

33.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
34.

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, Landen JW.

Mov Disord. 2008 Oct 15;23(13):1860-6. doi: 10.1002/mds.22169.

35.

Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13309-14. doi: 10.1073/pnas.0708850105. Epub 2008 Aug 29.

36.

Synthesis of novel pyrrolo[3,4-d]pyrazole-dicarboxylic acids and evaluation of their interaction with glutamate receptors.

Conti P, di Ventimiglia SJ, Pinto A, Tamborini L, Menniti FS, Lazzaro JT, De Micheli C.

Chem Biodivers. 2008 Apr;5(4):657-63. doi: 10.1002/cbdv.200890061.

PMID:
18421758
37.

PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia.

Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS.

Schizophr Res. 2008 Apr;101(1-3):36-49. doi: 10.1016/j.schres.2008.01.029. Epub 2008 Apr 3.

PMID:
18394866
38.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
39.
40.

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.

Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, Papa SM.

J Pharmacol Exp Ther. 2007 Oct;323(1):318-26. Epub 2007 Jul 13.

PMID:
17630359
41.

Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity.

Morissette M, Jourdain S, Al Sweidi S, Menniti FS, Ramirez AD, Di Paolo T.

Neuropharmacology. 2007 Jun;52(7):1509-20. Epub 2007 Mar 2.

PMID:
17420033
42.

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ.

Curr Opin Investig Drugs. 2007 Jan;8(1):54-9. Review.

PMID:
17263185
43.

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Chappie TA, Humphrey JM, Allen MP, Estep KG, Fox CB, Lebel LA, Liras S, Marr ES, Menniti FS, Pandit J, Schmidt CJ, Tu M, Williams RD, Yang FV.

J Med Chem. 2007 Jan 25;50(2):182-5.

PMID:
17228859
44.

Phosphodiesterases in the CNS: targets for drug development.

Menniti FS, Faraci WS, Schmidt CJ.

Nat Rev Drug Discov. 2006 Aug;5(8):660-70. Review.

PMID:
16883304
45.

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.

Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT.

J Histochem Cytochem. 2006 Nov;54(11):1205-13. Epub 2006 Jul 24.

PMID:
16864896
46.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
47.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):374-85. Epub 2006 Jun 12.

PMID:
16769090
48.

Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS.

Neuroscience. 2006 May 12;139(2):597-607. Epub 2006 Feb 17.

49.

Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.

Zappalà M, Postorino G, Micale N, Caccamese S, Parrinello N, Grazioso G, Roda G, Menniti FS, De Sarro G, Grasso S.

J Med Chem. 2006 Jan 26;49(2):575-81.

PMID:
16420043
50.

Molecular mechanism of AMPA receptor noncompetitive antagonism.

Balannik V, Menniti FS, Paternain AV, Lerma J, Stern-Bach Y.

Neuron. 2005 Oct 20;48(2):279-88.

Supplemental Content

Loading ...
Support Center